Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma.

Journal of biomolecular structure & dynamics - 1 Apr 2024

Balaji E Vignesh, Satarker Sairaj, Kumar B Harish, Pandey Samyak, Birangal Sumit Raosaheb, Nayak Usha Y, Pai K Sreedhara Ranganath

Abstract excerpt

Glioblastoma (GBM) is an aggressive malignant type of brain tumor. Targeting one single intracellular pathway might not alleviate the disease, rather it activates the other molecular pathways that lead to the worsening of the disease condition. Therefore, in this study, we attempted to target both isocitrate dehydrogenase 1 (IDH1) and IDH2, which are one of the most commonly mutated proteins in GBM and other...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioblastoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Source

Identifiers

PMID: 37227789
DOI: 10.1080/07391102.2023.2215884

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma.PMID 37227789Read ↗

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.Semantic proximity Read ↗

Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapy.Semantic proximity Read ↗

Identification and characterization of a novel mutant isocitrate dehydrogenase 1 inhibitor for glioma treatment.Semantic proximity Read ↗

Exploration of natural product database for the identification of potent inhibitor against IDH2 mutational variants for glioma therapySemantic proximity Read ↗

Computational study on novel natural compound inhibitor targeting IDH1_R132H.Semantic proximity Read ↗

Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers.Semantic proximity Read ↗

Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.Semantic proximity Read ↗

Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.Semantic proximity Read ↗

Virtual mutagenesis of isocitrate dehydrogenase 1 involved in glioblastoma multiforme.Semantic proximity Read ↗

Molecular modeling studies to discover novel mIDH2 inhibitors with high selectivity for the primary and secondary mutants.Semantic proximity Read ↗

Understanding the IDH1 missense SNPs on expression of genes involved in Glioblastoma multiforme.Semantic proximity Read ↗

Machine learning-driven discovery of potent isocitrate dehydrogenase 1 mutant inhibitors from ultralarge ligand libraries for targeting malignant glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.